A systematic review and meta-analysis of recombinant human soluble thrombomodulin for the treatment of DIC associated with hematological malignancies.
Noriaki KawanoMasahiko FukatsuKazuma YamakawaYoshinobu SekiHideo WadaKohji OkamotoTakayuki IkezoePublished in: International journal of hematology (2024)
Use of rhTM in patients with hematological malignancy-associated DIC is strongly expected to be effective and safe.